Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nichi-Iko to Shift to 2-Headquarters System in Oct.
August 15, 2012
- Otsuka HD’s April-June Pharma Sales Up 2.7% Despite Decline in Abilify Sales
August 15, 2012
- RaQualia Representative Director Nagahisa Steps Down, Mr Tani Appointed New Representative Director
August 15, 2012
- Asahi Kasei in Hot Pursuit of Eli Lilly Japan as Competition Heats Up in Market for Bone Formation Agents
August 13, 2012
- Over 20% of Doctors Report Decline in Meetings with MRs Since Revision of Business Entertainment GLs in April: CareNet Survey
August 13, 2012
- Business Strategies of Generics Manufacturers Become Evident Ahead of Upcoming Round of Patent Expiries
August 13, 2012
- Astellas Concludes Marketing Agreement with Nippon Kayaku for Vascular Embolization Material
August 10, 2012
- Takeda Terminates PIII Trial for AMG 479 for Pancreatic Cancer in Japan
August 10, 2012
- Up to 50% of Doctors Know About “Established Products” as Recognition Levels Rise: Pfizer Survey
August 9, 2012
- Mylan Transfers Exclusive Rights to Pfizer to Market EpiPen in Japan
August 9, 2012
- Shionogi’s Korean Partner Obtains Approval for Pirespa
August 9, 2012
- Astellas Applies for Irribow OD Tablet
August 9, 2012
- Ethical Drug Sales Down 0.3% in June: Crecon Report
August 8, 2012
- Hospira Files Additional Indication for Precedex for Non-Intubated Patients
August 8, 2012
- Daiichi Sankyo to Strengthen Cardiovascular Field by Comarketing Diabetes Treatments, Focusing on SGLT-2 Inhibitor
August 8, 2012
- 6 Listed Wholesalers Post Low Price Settlement Rates as of End-June, Showing Declines Compared to 2 Years Earlier
August 7, 2012
- Astellas to Close US Subsidiary for Urology Research
August 7, 2012
- Fuji Pharma to Acquire Thailand’s Largest Contract Manufacturer, to Make It Base of Overseas Operations
August 7, 2012
- Japan BCG Laboratory, Nippon Kayaku to Copromote Immunobladder
August 7, 2012
- Astellas to “Seek Every Opportunity” for Domestic Vaccine Business, Including Alliances with Foreign Companies
August 6, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…